• 본문 바로가기(Skip Contents)
ENGLISH
  • KOREAN
  • HOME

corestem

  • ABOUT US
    • Overview
    • History
    • Manufacturing facility
    • Our Company
  • PRODUCT
    • ALS (NeuroNata-R®)
    • Lou Gehrig's disease
  • PIPELINE
    • Pipeline
    • SLE
    • CA
  • R&D
    • Stem Cell Therapy
  • IR
    • Stock Information
    • Disclosures
    • Finances
    • Announcement of Settlement
    • IR Inquiry
  • PR
    • Press Report
    • Notice
    • Media
    • Online Inquiry

전체메뉴

전체메뉴

  • ABOUT US

    Overview History Manufacturing facility Our Company
  • PRODUCT

    ALS (NeuroNata-R®) Lou Gehrig's disease
  • PIPELINE

    Pipeline SLE CA
  • R&D

    Stem Cell Therapy
  • IR

    Stock Information Disclosures Finances Announcement of Settlement IR Inquiry
  • PR

    Press Report Notice Media Online Inquiry
  • HOME
ENGLISH
  • KOREAN
  • ABOUT US
    • Overview
    • History
    • Manufacturing facility
    • Our Company
  • PRODUCT
    • ALS (NeuroNata-R®)
    • Lou Gehrig's disease
  • PIPELINE
    • Pipeline
    • Target Disease
    • Lupus
  • R&D
    • Stem Cell Therapy
  • IR
    • Stock Information
    • Disclosures
    • Finances
    • Announcement of Settlement
    • IR Inquiry
  • PR
    • Press Report
    • Notice
    • Media
    • Online Inquiry

PR

Corestem is a biopharmaceutical company that researches and commercializes stem cell technology.

  • Press Report
  • Notice
  • Media
  • Online Inquiry
  • Press Report
  • Notice
  • Media
  • Online Inquiry

언론보도

  • 2019.07.23
    코아스템의 자신감…루게릭병 치료제 임상3상 '스타트

    ​줄기세포 치료제 '뉴로나타-알주 임상3상 연구자 미팅' 개최…"임상구조 개선, 효능 입증하고 ..

  • 2019.07.05
    코아스템, `혁신형 제약기업` 연장‥ 3년간 추가 ..

    코아스템, `혁신형 제약기업` 연장‥ 3년간 추가 정부지원 최봉선기자 cbs@medipana.c..

  • 2019.05.27
    코아스템, 루게릭병 치료제 美 FDA Pre-IND 신..

    코아스템, 루게릭병 치료제 美 FDA Pre-IND 신청완료 코아스템(166480)은 루게릭병 줄기세..

  • 2019.04.15
    [바이오리더 2019]⑦ 김경숙 코아스템 대표 “줄기..

    [바이오리더 2019]⑦ 김경숙 코아스템 대표 “줄기 세포 한국이 선도 가능...정부 지원 절실” ..

  • 2019.04.03
    코아스템, `뉴로나타알-주` 유럽의약품청 희귀의약품 지

    코아스템, `뉴로나타알-주` 유럽의약품청 희귀의약품 지정 김현정기자 입력 : 2019.04.03 0..

  • 2018.12.19
    SK증권 기업분석 리포트_코아스템

    SK증권 Analyst 서충우원문 : SK증권(https://www.sks.co.kr) - 투자정보 - 분석..

  • 6
  • 7
  • 8
  • 9
  • 10
  • ABOUT US
    Overview History Manufacturing facility Our Company
  • PRODUCT
    ALS (NeuroNata-R®) Lou Gehrig's disease
  • PIPELINE
    Pipeline Target Disease Lupus
  • R&D
    Stem Cell Therapy
  • IR
    Stock Information Disclosures Finances Announcement of Settlement IR relations
  • PR
    Press Report Notice Media Online Inquiry

Contact Information
  • 24, Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea
  • Gen (02) 497-3711
  • IR DID 070-4706-3546
  • FAX (02) 6349-8666
  • E-MAIL corestem@corestem.com
Copyright 2018 CORESTEM, Inc All right reserved.